DEFA14A: Iterum Urges Shareholders to Vote Ahead of EGM

Iterum Therapeutics plc reminds shareholders to cast their votes for the upcoming Extraordinary General Meeting by February 17, 2026, with the board and ISS recommending 'FOR' all four proposals.

Summary

• Iterum Therapeutics plc is reminding shareholders to vote their shares for the Extraordinary General Meeting (EGM) scheduled for February 18, 2026.
• The EGM will address four proposals that were described in the definitive proxy statement filed with the U.S. Securities and Exchange Commission on January 2, 2026.
• The company's board of directors has unanimously recommended that shareholders vote FOR each of the four proposals.
• Leading proxy advisory firm, Institutional Shareholder Services (ISS), also recommends voting FOR each proposal.
• Shareholders must cast their votes no later than February 17, 2026, at 11:59 PM ET to be counted, if not attending the meeting in person.
• Voting can be done quickly and easily online or by phone, with assistance available from proxy solicitor Campaign Management at 1-888-725-4553 or info@campaign-mgmt.com.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It is a procedural reminder for a shareholder vote, with no negative operational or financial news. The unanimous board recommendation and ISS endorsement for the proposals suggest a coordinated effort towards a positive outcome for the company, though the specifics of the proposals are not detailed here.

Positives

• The board of directors has unanimously recommended voting FOR all four proposals, indicating internal alignment.
• Institutional Shareholder Services (ISS), a leading proxy advisory firm, also recommends voting FOR each proposal, providing external validation for the board's recommendations.

Future Outlook

This filing is a procedural reminder for an upcoming shareholder vote and does not contain specific forward-looking statements regarding financial performance or operational guidance. The outcome of the four proposals to be voted on will influence the company's future direction, but the details of these proposals are not provided here.

Management Comments

• "We are reaching out as a reminder to please VOTE YOUR SHARES in advance of our extraordinary general meeting of shareholders scheduled on February 18, 2026."
• "Our board of directors has unanimously recommended that shareholders vote FOR each of the proposals, as does leading proxy advisory firm, Institutional Shareholder Services."
• "Please vote in favor of each proposal today to support Iterum Therapeutics plc."
• "YOUR VOTE IS IMPORTANT REGARDLESS OF HOW MANY SHARES YOU OWN."
• "If you have not voted yet, please do so today. Your vote must be cast no later than February 17, 2026, at 11:59 PM ET to be counted, if you do not plan to attend the meeting in person. Every vote counts."

Industry Context

This communication represents a standard corporate governance practice for publicly traded companies, particularly in advance of significant shareholder meetings. The engagement of a proxy solicitor and the endorsement from a major proxy advisory firm like Institutional Shareholder Services are common strategies to encourage shareholder participation and guide voting decisions on important corporate matters.

Comparison to Industry Standards

• The company's proactive communication with shareholders, including reminders and providing contact for voting assistance, aligns with best practices in corporate governance for public companies.
• The unanimous board recommendation and endorsement from Institutional Shareholder Services (ISS) are standard elements in proxy solicitations, aiming to influence shareholder votes in line with management's and independent advisors' views.

Corporate Governance

Stakeholder Impact

• Shareholders: Directly impacted by the call to vote on proposals that will affect the company's future. Their participation is crucial for the EGM's outcome and the implementation of the board's recommended actions.

Next Steps

• Shareholders are encouraged to vote their shares by the deadline of February 17, 2026, at 11:59 PM ET.
• The Extraordinary General Meeting of shareholders will take place on February 18, 2026.

Key Dates

Keywords

Iterum Therapeutics, EGM, Shareholder Vote, Proxy Statement, Corporate Governance, ISS Recommendation